BioGaia AB Class B ((GB:0GTN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioGaia AB is conducting a study titled ‘A Double-blind, Multi-center, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic.’ The primary objective is to assess the impact of L. reuteri on reducing crying time in infants suffering from colic, a common condition that causes significant distress for infants and their families.
The intervention being tested is a dietary supplement containing L. reuteri, administered as five drops daily for 21 days. This probiotic is intended to alleviate symptoms of colic by potentially improving gut health and reducing inflammation.
The study is designed as a randomized, placebo-controlled trial with a parallel-group model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on August 22, 2022, and is currently in the recruiting phase. The last update was submitted on September 17, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
This study could have significant market implications for BioGaia AB, as positive results may enhance the company’s product portfolio and boost investor confidence. In the competitive probiotics market, demonstrating efficacy in treating infant colic could differentiate BioGaia’s offerings and potentially improve its stock performance.
The study is ongoing, and further details are available on the ClinicalTrials portal.